Drug Trial Radar · NCT03792555
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)
Last checked: Nov 20, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Mar 11, 2019
Primary completion
Jul 15, 2020
Study completion Aug 12, 2020
Sponsor
- Lead sponsor
- Crinetics Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 3, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2 double-blind, placebo-controlled, randomized withdrawal study is designed to evaluate the safety, efficacy, and pharmacokinetics of paltusotine (formerly CRN00808) in subjects with acromegaly that are responders to octreotide LAR or lanreotide depot.
Conditions
- Acromegaly
Interventions
PaltusotineDrug
Paltusotine, capsules, once daily by mouth
PlaceboDrug
Placebo, capsules, once daily by mouth
Primary outcomes
What the sponsor says the trial is designed to measure.
- Responder Criteria Was Based on the Mean of Two Consecutive Insulin-like Growth Factor-1 [IGF-1] Measurements ≤ULN at Week 13Time frame: 13 Weeks
Locations
11 sites in 8 countries. Site status is shown where the registry gives one.
Ohio State University
Columbus, Ohio
The Research Institute of Dallas
Dallas, Texas
CETI - Centro de Estudos em Terapias Inovadoras
Curitiba, Brazil
CPQuali Pesquisa Clinica
São Paulo, Brazil
General Hospital of Athens "Gennimatas"
Athens, Greece
Semmelweis University Faculty of Medicine
Budapest, Hungary
University of Pécs Medical School
Pécs, Hungary
Endocrine, Diabetes and Research Centre, Wellington Hospital
Wellington, New Zealand
The Centre of Postgraduate Medical Education
Warsaw, Poland
Clinical Centre Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases
Belgrade, Serbia
National Institute of Endocrinology and Diabetology
Ľubochňa, Slovakia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.